- recruiting
Does synbiotic supplementation improve the effects of a ketogenic diet?
This study looks at whether a supplement called a synbiotic can help reduce "bad" cholesterol increases when people follow a ketogenic diet. We want to see if it helps keep gut bacteria healthy and prevents cholesterol from going too high, making ketogenic diets safer.
United Kingdom · England - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A clinical study of MK-3214 in healthy people (MK-3214-001)
This study is testing a new medicine, MK-3214, for people with high cholesterol. We want to see how safe it is and how it works in healthy men. It's an early-stage study to understand the medicine better.
Belgium - active not recruitingPHASE3
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
This study looks at a new daily pill, enlicitide decanoate, for people at high risk of heart problems like heart attacks or strokes. It aims to see if this pill can help reduce these serious events safely, compared to a dummy pill.
United States · Argentina · Australia - recruitingPHASE1
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
This study is testing a new medicine called CTX310 for people in the UK with high cholesterol and fats in their blood that haven't improved with usual treatments. It will check if the medicine is safe and how well people tolerate different doses. It's an early-stage study.
United States · Australia · New Zealand - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A clinical trial of MK-3214 taken with different liquids in healthy participants (MK-3214-002)
This study is testing a new medicine called MK-3214 in healthy men. It wants to see how the medicine works when taken with different drinks. The goal is to understand how the body handles this medicine, which might help people with high cholesterol in the future.
Belgium - recruitingPHASE3
Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days
This study compares two cholesterol-lowering medicines, obicetrapib and bempedoic acid, in adults with high cholesterol or mixed dyslipidemia. It looks at how well they reduce 'bad' cholesterol (LDL-C) and if they are safe, especially for people at higher risk of heart problems.
United Kingdom